Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines Under Normoxic and Hypoxic Conditions

Breast Cancer: Basic and Clinical Research - New Zealand
doi 10.4137/bcbcr.s13693
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer

International Journal of Oncology
Cancer ResearchOncology
2013English

NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro

Acta Pharmacologica Sinica
MedicinePharmacology
2013English

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2020English

BEZ235 Impairs Gastric Cancer Growth by Inhibition of PI3K/mTOR in Vitro and in Vivo

BMC Pharmacology
2010English

Primary Culture of Mouse Adipose and Fibrous Synovial Fibroblasts Under Normoxic and Hypoxic Conditions

Biomedical Research
BiochemistryMedicineGeneticsMolecular Biology
2020English

Cell Killing Efficacy of Combined Electroporation and Drug Delivery of NVP-BEZ235

Journal of Vascular and Interventional Radiology
Nuclear MedicineRadiologyCardiologyCardiovascular MedicineImagingMedicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy